Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
NCT ID: NCT06524427
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1124 participants
INTERVENTIONAL
2020-08-25
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RATS group
Patients will receive robot-assisted lobectomy
Robot-assisted lobectomy
Patients will receive robot-assisted lobectomy using Da Vinci surgical system
VATS group
Patients will receive video-assisted lobectomy
Video-assisted lobectomy
Patients will receive video-assisted lobectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Robot-assisted lobectomy
Patients will receive robot-assisted lobectomy using Da Vinci surgical system
Video-assisted lobectomy
Patients will receive video-assisted lobectomy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with blood pressure\<160/100mmHg, 5.6\<blood glucose\<11.2mmol/L, major organs function normally: (1) Goldman index between grade 1 and 2; (2) Predicted forced expiratory volume in 1s (FEV1) \>= 40 % and diffusing capacity of the lung for carbon monoxide (DLCO) \>= 40 %; (3) total bilirubin \<= 1.5 upper limit of normal; (4) Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) \<= 2.5 upper limit of normal; (5) creatinine \<= 1.25 upper limit of normal and creatinine clearance rate (CCr) \>= 60ml/min;
3. The first clinical diagnosis before surgery was non-small cell lung cancer, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other unknown types;
4. Clinical stage T1-2N0-1 (cI-II): Maximum diameter of tumor \<= 5cm and short diameter of mediastinal lymph node \<= 1cm in thin layer CT;
5. Performance status of Eastern Cooperative Oncology Group (ECOG) 0-1;
6. All relevant examinations were completed within 28 days before the operation;
7. Patients who understand this study and have signed an approved Informed Consent.
Exclusion Criteria
2. Patients with the previous history of other malignancies;
3. Patients with secondary primary cancer when enrolled;
4. Patients diagnosed as pure ground glass opacity (GGO) before surgery;
5. Patients diagnosed as mixed GGO whose solid part \<= 50% and Maximum diameter of tumor \<= 2cm;
6. Patients with small cell lung cancer;
7. Patients with prior unilateral open thoracic surgical procedures;
8. Woman who is pregnant or breastfeeding;
9. Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema;
10. Patients with an active bacterial or fungal infection that is difficult to control;
11. Patients with serious psychosis;
12. Patients with a history of severe heart attack, heart failure, myocardial infarction, or angina within the last 6 months.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Nanchang University
OTHER
The Affiliated Hospital of Qingdao University
OTHER
The General Hospital of Eastern Theater Command
OTHER
Gansu Provincial Hospital
OTHER
Tang-Du Hospital
OTHER
Wuhan TongJi Hospital
OTHER
First Affiliated Hospital of Chongqing Medical University
OTHER
West China Hospital
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Shenzhen People's Hospital
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Shandong Provincial Hospital
OTHER_GOV
Jiangsu Cancer Institute & Hospital
OTHER
Guangdong Provincial People's Hospital
OTHER
Liaoning Cancer Hospital & Institute
OTHER
Qilu Hospital of Shandong University
OTHER
Jiangxi Provincial People's Hopital
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
Lanzhou University Second Hospital
OTHER
Shenzhen Third People's Hospital
OTHER
Qianfoshan Hospital
OTHER
Guangxi Nanxishan Hospital
UNKNOWN
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hao-Xian Yang
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hao-Xian Yang, M.D.
Role: PRINCIPAL_INVESTIGATOR
Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Gansu Provincial Hospital
Lanzhou, Gansu, China
The Second Hospital of Lanzhou University
Lanzhou, Gansu, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Shenzhen Third People's Hospital
Shenzhen, Guangdong, China
Guangxi Nanxishan Hospital
Guilin, Guangxi, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Wuhan Union Hospital
Wuhan, Hubei, China
Wuhan TongJi Hospital
Wuhan, Hubei, China
The General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China
Jiangsu Cancer Institute & Hospital
Nanjing, Jiangsu, China
Jiangxi Provincial People's Hopital
Nanchang, Jiangxi, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Liaoning Tumor Hospital & Institute
Shenyang, Liaoning, China
Tang-Du Hospital
Xi'an, Shaanxi, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Qianfoshan Hospital
Jinan, Shandong, China
Shandong Provincial Hospital
Jinan, Shandong, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, China
West China Hospital
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ming Du, M.D.
Role: primary
Yun-Jiu Gou, M.D.
Role: primary
Bin Li, M.D.
Role: primary
Hao-Xian Yang, M.D.
Role: primary
Mu-Zi Yang, M.D.
Role: backup
Gui-Bin Qiao, M.D.
Role: primary
Guang-Suo Wang, M.D.
Role: primary
Kun Qiao, M.D.
Role: primary
Rong-Sheng Xiong, M.D.
Role: primary
Yu Qi, M.D.
Role: primary
Yong-De Liao, M.D.
Role: primary
Ni Zhang, M.D.
Role: primary
Jun Yi, M.D.
Role: primary
Ming Li, M.D.
Role: primary
Quan Xu, M.D.
Role: primary
Ben-Tong Yu, M.D.
Role: primary
Hong-Xu Liu, M.D.
Role: primary
Xiao-Long Yan, M.D.
Role: primary
Wei-Ming Yue, M.D.
Role: primary
Hui Tian, M.D.
Role: primary
Zhong-Min Peng, M.D.
Role: primary
Wen-Jie Jiao, M.D.
Role: primary
Bin Hu, M.D.
Role: primary
Yun Wang, M.D.
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
This clinical trial has been registered in Chinese Clinical Trial Registry with a registration number as ChiCTR2000034737
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChiCTR2000034737
Identifier Type: REGISTRY
Identifier Source: secondary_id
SL-5010-2019-04
Identifier Type: -
Identifier Source: org_study_id